Botanix Pharmaceuticals Ltd (ASX: BOT) a dermatology company who is into delivering is currently targeting synthetic cannabinoids for skin disease treatment is now focusing on its multi-billion-dollar prescription markets that take care of acne, atopic dermatitis, and psoriasis. The company is developing a synthetic form of cannabidiol “Epidiolex” which has received a safety profile. The Epidiolex has received approvals from FDA which increases the probability if the product. In the clinical trial of acne and atopic dermatitis patient, the test was successful after treating the patient for four weeks. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
Permetrex which is BOT’s Novel skin delivery technology has the potential to deliver cannabidiol into the skin as compared to the traditional formulation approaches. Botanix pharmaceuticals have a set of experienced teams which is a US-based leadership team holding 20+ FDA approvals. Permetrex technology has excellent delivery of cannabidiol as it reaches the targeted layers of skin.
In phase 2, the acne and atopic dermatitis program will be undergoing an exciting development pipeline program, and Permetrex will support the development program which in turn will add revenues to the company. There are four development pipeline which includes BTX 1503 which is a lead product for moderate to severe acne, BTX 1204 which will0-9 treat mild to moderate atopic dermatitis also known as eczema, BTX 1308 will treat patients of psoriasis, and BTX 1801 will be addressing unmet needs of the skin infections
The clinical trials of BTX 1503 for four weeks have given an outstanding result where data reports that there was a reduction in the inflammatory lesions which is greater than other acne products. Twelve weeks of the study proved that it is safe for patients with moderate to severe acne. The next step taken by the BOT was the commercialization of the product to add revenues to the company. Phase 2 of the clinical trial is in progress and is expected to get complete by early 3Q of CY2019 approximately.
BTX 1204 will be treating an inflammatory disease of the skin. Atopic dermatitis and psoriasis are both a form of the T-cell mediated inflammatory disease. The trial phase of BTX 1204 was successful after four weeks of the treatment period, and its phase 1 study got completed in the late May 2018. Twelve weeks of the randomized study proved the safety 6and efficacy of the BTX 1204 in patients.
The clinical studies of BTX 1308 have started to test it against a vehicle and already marketed psoriasis drug in patients. The results from the data proved that BTX 1308 has the potential to treat the unmet needs of the skin infection through new antimicrobial along with other benefits such as inflammation reduction.
The studies have created a positive impact on investors as a result of which the by the end of trading on 12 December 2018, the market price of the share increased by 1.389% to $0.073 with the stock holding a market capitalization of A$54.53 million.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.